Plasma magnesium and the risk of new-onset hyperuricemia in hypertensive patients.

Plasma magnesium and the risk of new-onset hyperuricemia in hypertensive patients. Br J Nutr. 2020 Mar 26;:1-22 Authors: Cao J, Zhang J, Zhang Y, Li H, Jiang C, Lin T, Zhou Z, Song Y, Liu C, Liu L, Wang B, Li J, Zhang Y, Cui Y, Huo Y, Wang X, Zhang H, Qin X, Xu X Abstract We aimed to evaluate the relationship of plasma magnesium with the risk of new-onset hyperuricemia, and examine any possible effect modifiers in hypertensive patients. This is a post-hoc analysis of the Uric acid (UA) Sub-study of the China Stroke Primary Prevention Trial (CSPPT). A total of 1685 participants were included in the current study. The main outcome was new-onset hyperuricemia defined as a UA concentration ≥417 μmol/L in men or ≥357 μmol/L in women. The secondary outcome was a change in UA concentration defined as UA at the exit visit minus that at baseline. During a median follow-up duration of 4.3 years, new-onset hyperuricemia occurred in 290 (17.2%) participants. There was a significantly inverse relation of plasma magnesium with the risk of new-onset hyperuricemia (per SD increment; OR, 0.85; 95%CI: 0.74, 0.99) and change in UA levels (per SD increment; β, -3.96 μmol/L; 95%CI: -7.14, -0.79). Consistently, when plasma magnesium was analyzed as tertiles, a significantly lower risk of new-onset hyperuricemia (OR, 0.67; 95%CI: 0.48, 0.95) and less increase in UA levels (β, -8.35μmol/L; 95%CI: -16.12, -0.58) were found among participants in ter...
Source: The British Journal of Nutrition - Category: Nutrition Authors: Tags: Br J Nutr Source Type: research